• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Risk-to-Price Commentary: Merck Finanz AG May 11 Product Image

Risk-to-Price Commentary: Merck Finanz AG May 11

  • Published: May 2011
  • Standard & Poors

FEATURED COMPANIES

  • AstraZeneca PLC
  • Bayer AG
  • Bayer Capital Corp. B.V.
  • Bristol-Myers Squibb Co.
  • Cegedim S.A.
  • FMC Finance VI S.A.
  • MORE

Abstract
Of the companies in the S&P Europe 350 Index, 135 have so far reported their calendar first-quarter earnings (197 in total are due to report this quarter), with a 57% positive surprise for all 10 aggregated sectors, according to Capital IQ data. The health care sector had 75% of its companies post positive surprises--the highest share among the 10 index sectors. The Valuation and Risk Strategies (VRS) research team looked at the Capital IQ forecast for the health care sector and found that the analysts' poll expects earnings to grow 33% over the current year, and then to subside to 7% in the following two years (see chart 1). The VRS research team then looked to see if European health...

Companies mentioned in this report are:
- Bristol-Myers Squibb Co.
- Johnson & Johnson
- Pfizer Inc.
- Millipore Corp.
- Bayer AG
- GlaxoSmithKline Capital PLC
- AstraZeneca PLC
- Sanofi
- Bayer Capital Corp. B.V.
- Fresenius U.S. Finance II Inc.
- Roche Finance Europe B.V.
- Merck Financial Services GmbH
- FMC Finance VI S.A.
- Cegedim S.A.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international READ MORE >

- Bristol-Myers Squibb Co.
- Johnson & Johnson
- Pfizer Inc.
- Millipore Corp.
- Bayer AG
- GlaxoSmithKline Capital PLC
- AstraZeneca PLC
- Sanofi
- Bayer Capital Corp. B.V.
- Fresenius U.S. Finance II Inc.
- Roche Finance Europe B.V.
- Merck Financial Services GmbH
- FMC Finance VI S.A.
- Cegedim S.A.

Note: Product cover images may vary from those shown

RELATED PRODUCTS